Wechselwirkungen · Filgrastim Hexal
Filgrastim HEXAL 30 MU/0.5 mL solution for injection or infusion in pre-filled syringe Filgrastim HEXAL 48 MU/0.5 mL solution for injection or infusion in pre-filled syringe · Abschnitt 4.5 · PDF-Seite 12
HOS-209637 · Präparat HOS-154345
The safety and efficacy of filgrastim given on the same day as myelosuppressive cytotoxic chemotherapy have not been definitively established. In view of the sensitivity of rapidly dividing myeloid cells to myelosuppressive cytotoxic chemotherapy, the use of filgrastim is not recommended in the period from 24 hours before to 24 hours after chemotherapy. Preliminary evidence from a small number of patients treated concomitantly with filgrastim and 5-fluorouracil indicates that the severity of neutropenia may be exacerbated.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-22T12:41:00Z · SHA-256 83b07123404f62aa7b58fc9646c7d49724612fc3405ea7378cdce408567ccc18 · Passage b5b6eb96ca2ebd92f7ebaf683172522bf77277faf465e67e341a31e107556457 · Zeichen 0–528 im Abschnitt